A female patient reports occasional dyspnea and a 15‑lb weight gain while taking escitalopram (Lexapro), propranolol, anastrozole, goserelin (Zoladex) and omeprazole; what could be causing these symptoms and what work‑up is recommended?

Dyspnea and Weight Gain in a Patient on Multiple Medications

The 15-lb weight gain is most likely attributable to propranolol and potentially omeprazole, while the dyspnea warrants urgent cardiac evaluation given the combination of beta-blocker therapy, aromatase inhibitor use, and recent weight gain. 1

Medication-Related Weight Gain

Primary Culprits

Propranolol is the most likely cause of the weight gain. Beta-blockers, particularly non-selective agents like propranolol, promote sustained weight gain through multiple mechanisms including decreased metabolic rate and adverse effects on energy metabolism 1. Long-term propranolol treatment results in mean weight gain of 2.3 kg at one year, with the difference persisting throughout treatment 2. This weight gain:

• Occurs regardless of age or sex 2
• Cannot be explained by changes in physical activity or diuretic use 2
• Begins early in treatment and continues throughout therapy 2

Omeprazole contributes additional weight gain risk. Long-term PPI therapy (mean 2.2 years) is associated with significant increases in body weight (mean 3.5 kg or 6.2% of baseline) and BMI in 71% of patients with GERD 3. This occurs despite lifestyle modification advice 3.

Secondary Contributors

Escitalopram (Lexapro) is generally weight-neutral but shows minimal weight gain with long-term use. While short-term SSRI use may cause weight loss, escitalopram demonstrates an average increase of only 0.14 kg (0.05-point BMI increase) over 12 weeks 4. Recent large-scale data confirms escitalopram causes modest weight gain (0.41 kg at 6 months) compared to sertraline, with 10-15% higher risk of gaining ≥5% baseline weight 5.

Anastrozole and goserelin (Zoladex) are not directly associated with weight gain but may contribute indirectly through menopausal symptoms and reduced activity 6.

Dyspnea Evaluation

Immediate Cardiac Assessment Required

The dyspnea requires urgent evaluation for heart failure and cardiac dysfunction. This patient has multiple risk factors:

• Beta-blocker use with dyspnea suggests possible cardiac decompensation, as propranolol should be used with caution in patients developing dyspnea 7
• Recent significant weight gain (15 lbs) may indicate fluid retention rather than adipose tissue accumulation 1
• Aromatase inhibitor therapy can cause cardiac dysfunction, though the evidence focuses more on bone and cholesterol effects 6

Differential Diagnosis for Dyspnea

Consider these specific etiologies:

• Cardiac causes: Heart failure (particularly given beta-blocker use and weight gain), cardiomyopathy, or pericardial disease 7, 8
• Pulmonary causes: Pleural effusion, pulmonary embolism (cancer-related hypercoagulability), or pneumonitis 9
• Cancer-related: Metastatic disease to lungs, malignant pleural effusion (7-15% of breast cancer patients), or anemia from treatment 9
• Medication-induced: Beta-blocker-related bronchospasm or cardiac depression 7, 10
• Obesity-related: Increased oxygen cost of breathing without bronchoconstriction 11

Recommended Work-Up

Essential Immediate Studies

Obtain the following tests urgently:

• Echocardiogram to assess cardiac function, ejection fraction, and rule out cardiomyopathy 7, 8
• BNP or NT-proBNP to evaluate for heart failure 8
• Chest X-ray to assess for pleural effusion, pulmonary metastases, or pneumonia 9
• Complete blood count to evaluate for anemia (common with cancer treatment) 9
• Comprehensive metabolic panel including liver function tests (anastrozole can cause liver inflammation) 6
• Lipid panel (anastrozole increases cholesterol) 6

Additional Considerations

If initial cardiac work-up is negative:

• Pulmonary function tests if obstructive symptoms present 11
• CT chest if malignancy-related dyspnea suspected 9
• D-dimer and CT pulmonary angiogram if pulmonary embolism suspected (cancer patients have increased thrombotic risk) 9

Management Recommendations

Medication Optimization

Consider switching propranolol to a cardioselective beta-blocker with vasodilating properties (carvedilol or nebivolol) if beta-blockade is required, as these have less potential for weight gain and minimal effects on lipid and glucose metabolism 1.

Evaluate the necessity of omeprazole. If PPI therapy must continue, counsel the patient that weight gain is an expected side effect requiring active lifestyle management 3.

Escitalopram can be continued as it shows minimal weight impact compared to alternatives, though bupropion would be the preferred antidepressant if weight loss is desired 1, 4, 5.

Critical Safety Monitoring

Monitor for anastrozole-related complications:

• Bone density testing (anastrozole causes bone thinning and increased fracture risk) 6
• Liver function (can cause hepatic inflammation) 6
• Cardiovascular symptoms (heart problems are listed as a precaution) 6

Watch for drug interactions: Escitalopram co-prescription significantly increases plasma anastrozole levels, particularly in obese patients (BMI >29 kg/m²), though this does not affect estradiol suppression 12. Close monitoring is warranted given the patient's weight gain 12.

Common Pitfalls to Avoid

Do not attribute all dyspnea to deconditioning or obesity without ruling out cardiac and pulmonary pathology, especially in a cancer patient on cardiotoxic medications 9, 8.

Do not discontinue beta-blocker abruptly if cardiac dysfunction is present, as this may worsen outcomes 7, 10.

Do not assume weight gain is purely dietary without considering medication effects and fluid retention 1, 3, 2.